<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Impact of neuraminidase inhibitors on influenza A(H1N1) pdm09-related pneumonia: an individual participant data meta-analysis</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Stella</forename><forename type="middle">G</forename><surname>Muthuri</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Epidemiology and Public Health</orgName>
								<orgName type="institution">University of Nottingham</orgName>
								<address>
									<settlement>Nottingham</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sudhir</forename><surname>Venkatesan</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Epidemiology and Public Health</orgName>
								<orgName type="institution">University of Nottingham</orgName>
								<address>
									<settlement>Nottingham</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Puja</forename><forename type="middle">R</forename><surname>Myles</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Epidemiology and Public Health</orgName>
								<orgName type="institution">University of Nottingham</orgName>
								<address>
									<settlement>Nottingham</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jo</forename><surname>Leonardi-Bee</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Epidemiology and Public Health</orgName>
								<orgName type="institution">University of Nottingham</orgName>
								<address>
									<settlement>Nottingham</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wei</forename><forename type="middle">Shen</forename><surname>Lim</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Respiratory Medicine</orgName>
								<orgName type="institution">Nottingham University Hospitals NHS Trust</orgName>
								<address>
									<settlement>Nottingham</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Abdullah</forename><surname>Al Mamun</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ashish</forename><forename type="middle">P</forename><surname>Anovadiya</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">International Centre for Diarrhoeal Diseases</orgName>
								<orgName type="institution">Research Bangladesh (ICDDRB)</orgName>
								<address>
									<settlement>Dhaka</settlement>
									<country key="BD">Bangladesh</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Department of Pharmacology</orgName>
								<orgName type="department" key="dep2">Government Medical College</orgName>
								<orgName type="institution">Sir Takhtsinhji General Hospital</orgName>
								<address>
									<settlement>Bhavnagar</settlement>
									<region>Gujarat</region>
									<country key="IN">India</country>
								</address>
							</affiliation>
							<affiliation key="aff48">
								<orgName type="laboratory">and Research Laboratory</orgName>
								<address>
									<country>University</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wildo</forename><forename type="middle">N</forename><surname>Ara</surname></persName>
							<affiliation key="aff4">
								<orgName type="institution">University of Bras ılia</orgName>
								<address>
									<addrLine>Bras ılia</addrLine>
									<region>DF</region>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Eduardo</forename><surname>Azziz-Baumgartner</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Centers for Disease Control and Prevention</orgName>
								<address>
									<settlement>Atlanta</settlement>
									<region>GA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Clarisa</forename><forename type="middle">B</forename><surname>Aez</surname></persName>
							<affiliation key="aff6">
								<orgName type="institution">Ministerio de Salud de la Provincia de Buenos Aires</orgName>
								<address>
									<settlement>Buenos Aires</settlement>
									<country key="AR">Argentina</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Carlos</forename><surname>Bantar</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Infection Control</orgName>
								<orgName type="institution">Hospital San Mart ın de Paran a</orgName>
								<address>
									<addrLine>Entre R ıos</addrLine>
									<country key="AR">Argentina</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mazen</forename><forename type="middle">M</forename><surname>Barhoush</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">King Saud Medical City</orgName>
								<address>
									<settlement>Riyadh</settlement>
									<country key="SA">Saudi Arabia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Matteo</forename><surname>Bassetti</surname></persName>
							<affiliation key="aff9">
								<orgName type="institution">Santa Maria Misericordia Hospital</orgName>
								<address>
									<settlement>Udine</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bojana</forename><surname>Beovic</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Department of Infectious Diseases</orgName>
								<orgName type="institution">University Medical Centre</orgName>
								<address>
									<settlement>Ljubljana</settlement>
									<country key="SI">Slovenia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Roland</forename><surname>Bingisser</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Department of Emergency Medicine</orgName>
								<orgName type="institution">University Hospital Basel</orgName>
								<address>
									<settlement>Basel</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Isabelle</forename><surname>Bonmarin</surname></persName>
							<affiliation key="aff12">
								<orgName type="institution">Institut de Veille Sanitaire</orgName>
								<address>
									<settlement>Saint-Maurice</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Victor</forename><forename type="middle">H</forename><surname>Borja-Aburto</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">Instituto Mexicano del Seguro Social (IMSS)</orgName>
								<address>
									<settlement>Mexico City</settlement>
									<country key="MX">Mexico</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bin</forename><surname>Cao</surname></persName>
							<affiliation key="aff14">
								<orgName type="institution" key="instit1">Beijing Chao-Yang Hospital</orgName>
								<orgName type="institution" key="instit2">Capital Medical University</orgName>
								<address>
									<settlement>Beijing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jordi</forename><surname>Carratala</surname></persName>
							<affiliation key="aff15">
								<orgName type="department" key="dep1">Department of Infectious Diseases</orgName>
								<orgName type="department" key="dep2">Red Española de Investigaci on en Patolog ıa Infecciosa</orgName>
								<orgName type="institution" key="instit1">Hospital Universitari de Bellvitge</orgName>
								<orgName type="institution" key="instit2">Bellvitge Institute for Biomedical Research</orgName>
								<orgName type="institution" key="instit3">L&apos;Hospitalet de Llobregat</orgName>
								<orgName type="institution" key="instit4">University of Barcelona</orgName>
								<address>
									<settlement>Barcelona</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mar</forename><surname>Ia</surname></persName>
							<affiliation key="aff21">
								<orgName type="laboratory">Clinical Virology Laboratory</orgName>
								<orgName type="institution">CEMIC University Hospital</orgName>
								<address>
									<settlement>Buenos Aires</settlement>
									<country key="AR">Argentina</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">R</forename><surname>Cuezzo</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Justin</forename><forename type="middle">T</forename><surname>Denholm</surname></persName>
							<affiliation key="aff16">
								<orgName type="institution">Ministerio de Salud de Tucum</orgName>
								<address>
									<addrLine>Tucum</addrLine>
									<country key="AR">Argentina</country>
								</address>
							</affiliation>
							<affiliation key="aff17">
								<orgName type="department" key="dep1">Department of Microbiology and Immunology</orgName>
								<orgName type="department" key="dep2">Peter Doherty Institute for Infection and Immunity</orgName>
								<orgName type="institution">Victorian Infectious Diseases Service</orgName>
								<address>
									<settlement>Parkville</settlement>
									<region>Vic</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Samuel</forename><forename type="middle">R</forename><surname>Dominguez</surname></persName>
							<affiliation key="aff18">
								<orgName type="department">Department of Pediatric Infectious Diseases</orgName>
								<orgName type="institution" key="instit1">Children&apos;s Hospital Colorado</orgName>
								<orgName type="institution" key="instit2">University of Colorado School of Medicine</orgName>
								<address>
									<settlement>Aurora</settlement>
									<region>CO</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pericles</forename><forename type="middle">A D</forename><surname>Duarte</surname></persName>
							<affiliation key="aff19">
								<orgName type="institution" key="instit1">Universidade Estadual do Oeste do Parana ´</orgName>
								<orgName type="institution" key="instit2">UNIOESTE</orgName>
								<address>
									<settlement>Cascavel</settlement>
									<region>PR</region>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gal</forename><surname>Dubnov-Raz</surname></persName>
							<affiliation key="aff20">
								<orgName type="institution" key="instit1">The Edmond and Lily Safra Children&apos;s Hospital</orgName>
								<orgName type="institution" key="instit2">Sheba Medical Center</orgName>
								<orgName type="institution" key="instit3">Tel-Hashomer</orgName>
								<address>
									<country key="IL">Israel</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marcela</forename><surname>Echavarria</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Sergio</forename><surname>Fanella</surname></persName>
							<affiliation key="aff22">
								<orgName type="department">Section of Pediatric Infectious Diseases</orgName>
								<orgName type="institution">University of Manitoba</orgName>
								<address>
									<settlement>Winnipeg</settlement>
									<region>MB</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">James</forename><surname>Fraser</surname></persName>
							<affiliation key="aff23">
								<orgName type="laboratory">Paediatric Intensive Care Unit</orgName>
								<orgName type="institution">Bristol Children&apos;s Hospital</orgName>
								<address>
									<settlement>Bristol</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Zhancheng</forename><surname>Gao</surname></persName>
							<affiliation key="aff24">
								<orgName type="department">Department of Respiratory &amp; Critical Care Medicine</orgName>
								<orgName type="institution">Peking University People&apos;s Hospital</orgName>
								<address>
									<settlement>Beijing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Patrick</forename><forename type="middle">G</forename><surname>Erardin</surname></persName>
							<affiliation key="aff25">
								<orgName type="institution" key="instit1">NICU/PICU</orgName>
								<orgName type="institution" key="instit2">PFME, CHU Saint Pierre</orgName>
								<address>
									<settlement>Saint Pierre, La</settlement>
								</address>
							</affiliation>
							<affiliation key="aff27">
								<orgName type="department">CHU/Inserm</orgName>
								<orgName type="laboratory">UMR PIMIT</orgName>
								<orgName type="institution" key="instit1">University of La Re ´union/IRD/CNRS)</orgName>
								<orgName type="institution" key="instit2">CYROI, Saint Denis -Reunion Island</orgName>
								<address>
									<settlement>Saint Denis</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff28">
								<orgName type="institution" key="instit1">NICU/PICU CHU of La Re ´union</orgName>
								<orgName type="institution" key="instit2">Groupe Hospitalier Sud Re ´union</orgName>
								<address>
									<addrLine>Saint Pierre, La Re ´union</addrLine>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Maddalena</forename><surname>Giannella</surname></persName>
							<affiliation key="aff29">
								<orgName type="department">Department of Clinical Microbiology and Infectious Diseases</orgName>
								<orgName type="institution">Hospital General Universitario Gregorio Maran ˜o ´n</orgName>
								<address>
									<settlement>Madrid</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sophie</forename><surname>Gubbels</surname></persName>
							<affiliation key="aff30">
								<orgName type="department">Department of Infectious Disease Epidemiology</orgName>
								<orgName type="institution" key="instit1">Sector for National Health Documentation and Research</orgName>
								<orgName type="institution" key="instit2">Statens Serum Institut</orgName>
								<address>
									<settlement>Copenhagen</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jethro</forename><surname>Herberg</surname></persName>
							<affiliation key="aff31">
								<orgName type="department">Division of Infectious Disease</orgName>
								<orgName type="institution" key="instit1">Section of Paediatrics</orgName>
								<orgName type="institution" key="instit2">Imperial College</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anjarath</forename><forename type="middle">L</forename><surname>Higuera Iglesias</surname></persName>
							<affiliation key="aff32">
								<orgName type="laboratory">Epidemiology Research Unit</orgName>
								<orgName type="institution" key="instit1">Instituto Nacional de Enfermedades Respiratorias</orgName>
								<orgName type="institution" key="instit2">Ismael Cosı ´o Villegas</orgName>
								<address>
									<settlement>Mexico City</settlement>
									<country key="MX">Mexico</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><forename type="middle">H</forename><surname>Hoeger</surname></persName>
							<affiliation key="aff33">
								<orgName type="institution">Cath. Children&apos;s Hospital Wilhelmstift</orgName>
								<address>
									<settlement>Hamburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Matthias</forename><surname>Hoffmann</surname></persName>
							<affiliation key="aff34">
								<orgName type="department">Division of Infectious Diseases and Hospital Epidemiology</orgName>
								<orgName type="institution">Kantonsspital St</orgName>
								<address>
									<settlement>Gallen, St. Gallen</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Xiaoyun</forename><surname>Hu</surname></persName>
							<affiliation key="aff35">
								<orgName type="institution">Peking Union Medical College Hospital</orgName>
								<address>
									<settlement>Beijing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Quazi</forename><forename type="middle">T</forename><surname>Islam</surname></persName>
							<affiliation key="aff36">
								<orgName type="institution">Dhaka Medical College Hospital</orgName>
								<address>
									<settlement>Dhaka</settlement>
									<country key="BD">Bangladesh</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mirela</forename><forename type="middle">F</forename><surname>Jim</surname></persName>
							<affiliation key="aff37">
								<orgName type="department">Departamento de Ginecologia e Obstetrı ´cia -UFCSPA</orgName>
								<orgName type="institution">Preceptora da Reside ˆncia Me ´dica do Hospital Fe ˆmina</orgName>
								<address>
									<settlement>Porto Alegre</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Amr</forename><surname>Kandeel</surname></persName>
							<affiliation key="aff38">
								<orgName type="institution">Ministry of Health in Egypt</orgName>
								<address>
									<settlement>Cairo</settlement>
									<country key="EG">Egypt</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gerben</forename><surname>Keijzers</surname></persName>
							<affiliation key="aff39">
								<orgName type="institution">Gold Coast Hospital</orgName>
								<address>
									<addrLine>Gold Coast</addrLine>
									<settlement>Qld</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hossein</forename><surname>Khalili</surname></persName>
							<affiliation key="aff40">
								<orgName type="department" key="dep1">Department of Clinical Pharmacy</orgName>
								<orgName type="department" key="dep2">Faculty of Pharmacy</orgName>
								<orgName type="institution">Tehran University of Medical Sciences</orgName>
								<address>
									<settlement>Tehran</settlement>
									<country key="IR">Iran</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gulam</forename><surname>Khandaker</surname></persName>
							<affiliation key="aff41">
								<orgName type="department">The Children&apos;s Hospital at Westmead</orgName>
								<orgName type="laboratory">National Centre for Immunisation Research and Surveillance (NCIRS)</orgName>
								<orgName type="institution">University of Sydney</orgName>
								<address>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marian</forename><surname>Knight</surname></persName>
							<affiliation key="aff42">
								<orgName type="department">Department of Population Health</orgName>
								<orgName type="institution">National Perinatal Epidemiology Unit</orgName>
								<address>
									<settlement>Nuffield</settlement>
								</address>
							</affiliation>
							<affiliation key="aff43">
								<orgName type="institution">University of Oxford</orgName>
								<address>
									<settlement>Oxford</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gabriela</forename><surname>Kusznierz</surname></persName>
							<affiliation key="aff44">
								<orgName type="institution">National Institute of Respiratory Diseases &apos;Emilio Coni&apos; ANLIS &quot;C. Malbran&quot;</orgName>
								<address>
									<settlement>Santa Fe</settlement>
									<country key="AR">Argentina</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ilija</forename><surname>Kuzman</surname></persName>
							<affiliation key="aff45">
								<orgName type="department">School of Medicine</orgName>
								<orgName type="institution" key="instit1">University Hospital for Infectious Diseases</orgName>
								<orgName type="institution" key="instit2">University of Zagreb</orgName>
								<address>
									<settlement>Zagreb</settlement>
									<country key="HR">Croatia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Arthur</forename><forename type="middle">M C</forename><surname>Kwan</surname></persName>
							<affiliation key="aff46">
								<orgName type="department" key="dep1">Department of Intensive Care</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine and Pharmacy</orgName>
								<orgName type="institution">Pamela Youde Nethersole Eastern Hospital</orgName>
								<address>
									<settlement>Chai Wan, Hong Kong. 47</settlement>
								</address>
							</affiliation>
							<affiliation key="aff47">
								<orgName type="institution" key="instit1">Mohammed V Military Teaching Hospital</orgName>
								<orgName type="institution" key="instit2">Biosafety Level</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Idriss</forename><forename type="middle">Lahlou</forename><surname>Amine</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Eduard</forename><surname>Langenegger</surname></persName>
							<affiliation key="aff49">
								<orgName type="department">Department of Obstetrics and Gynaecology</orgName>
								<orgName type="institution">Stellenbosch University and Tygerberg</orgName>
								<address>
									<settlement>Stellenbosch</settlement>
									<country key="ZA">South Africa</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kamran</forename><forename type="middle">B</forename><surname>Lankarani</surname></persName>
							<affiliation key="aff50">
								<orgName type="institution" key="instit1">Health Policy Research Center</orgName>
								<orgName type="institution" key="instit2">Shiraz University of Medical Sciences</orgName>
								<address>
									<settlement>Shiraz</settlement>
									<country key="IR">Iran</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yee-Sin</forename><surname>Leo</surname></persName>
							<affiliation key="aff51">
								<orgName type="department">Department of Infectious Diseases</orgName>
								<orgName type="institution">Tan Tock Seng Hospital</orgName>
								<address>
									<settlement>Singapore</settlement>
									<country key="SG">Singapore</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rita</forename><surname>Linko</surname></persName>
							<affiliation key="aff52">
								<orgName type="institution">Helsinki University Hospital</orgName>
								<address>
									<settlement>Helsinki</settlement>
									<country key="FI">Finland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pei</forename><surname>Liu</surname></persName>
							<affiliation key="aff53">
								<orgName type="department">Department of Infectious Diseases</orgName>
								<orgName type="institution">The First Affiliated Hospital</orgName>
							</affiliation>
							<affiliation key="aff54">
								<orgName type="institution">China Medical University</orgName>
								<address>
									<settlement>Shenyang</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Faris</forename><surname>Madanat</surname></persName>
							<affiliation key="aff55">
								<orgName type="department">Department of Pediatrics</orgName>
								<address>
									<addrLine>King Hussein Cancer Center</addrLine>
									<settlement>Amman</settlement>
									<country key="JO">Jordan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Toshie</forename><surname>Manabe</surname></persName>
							<affiliation key="aff56">
								<orgName type="department">Graduate School of Comprehensive Human Sciences</orgName>
								<orgName type="institution">University of Tsukuba</orgName>
								<address>
									<settlement>Tsukuba</settlement>
									<region>Ibaraki</region>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Elga</forename><surname>Mayo-Montero</surname></persName>
							<affiliation key="aff57">
								<orgName type="institution" key="instit1">Instituto de Medicina Preventiva de la Defensa</orgName>
								<orgName type="institution" key="instit2">Capitan Medico Ramon y Cajal (IMPDEF)</orgName>
								<address>
									<addrLine>Ministerio de Defensa</addrLine>
									<settlement>Madrid</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Allison</forename><surname>Mcgeer</surname></persName>
							<affiliation key="aff58">
								<orgName type="department">Toronto Invasive Bacterial Diseases Network</orgName>
								<orgName type="institution">University of Toronto</orgName>
								<address>
									<settlement>Toronto</settlement>
									<region>ON</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ziad</forename><forename type="middle">A</forename><surname>Memish</surname></persName>
							<affiliation key="aff59">
								<orgName type="department">Saudi Arabia. 58 College of Medicine</orgName>
								<orgName type="institution">Ministry of Health</orgName>
								<address>
									<settlement>Riyadh</settlement>
								</address>
							</affiliation>
							<affiliation key="aff60">
								<orgName type="institution">Alfaisal University</orgName>
								<address>
									<settlement>Riyadh</settlement>
									<country key="SA">Saudi Arabia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gokhan</forename><surname>Metan</surname></persName>
							<affiliation key="aff61">
								<orgName type="department" key="dep1">Department of Infectious Diseases and Clinical Microbiology</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="institution">Erciyes University</orgName>
								<address>
									<settlement>Kayseri</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dragan</forename><surname>Miki</surname></persName>
							<affiliation key="aff62">
								<orgName type="department">Clinic for Infectious and Tropical Diseases</orgName>
								<orgName type="institution">Military Medical Academy</orgName>
								<address>
									<settlement>Belgrade</settlement>
									<country key="RS">Serbia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kristin</forename><forename type="middle">G I</forename><surname>Mohn</surname></persName>
							<affiliation key="aff63">
								<orgName type="department" key="dep1">Section for Infectious Diseases</orgName>
								<orgName type="department" key="dep2">Medical Department</orgName>
								<orgName type="department" key="dep3">Department of Research and Development</orgName>
								<orgName type="institution">Haukeland University Hospital</orgName>
								<address>
									<settlement>Bergen</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
							<affiliation key="aff64">
								<orgName type="department" key="dep1">Department of Clinical Science</orgName>
								<orgName type="department" key="dep2">The Influenza Centre</orgName>
								<orgName type="institution">University of Bergen</orgName>
								<address>
									<settlement>Bergen</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ahmadreza</forename><surname>Moradi</surname></persName>
							<affiliation key="aff65">
								<orgName type="department">Department of Ophthalmology</orgName>
								<orgName type="institution" key="instit1">The Division of Ocular Immunology</orgName>
								<orgName type="institution" key="instit2">Johns Hopkins University School of Medicine</orgName>
								<address>
									<settlement>Baltimore</settlement>
									<region>MD</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff66">
								<orgName type="institution" key="instit1">National Research Institute for Tuberculosis and Lung Disease</orgName>
								<orgName type="institution" key="instit2">Massih Daneshvari Hospital</orgName>
								<orgName type="institution" key="instit3">Shahid Beheshti University of Medical Sciences</orgName>
								<address>
									<settlement>Tehran</settlement>
									<country key="IR">Iran</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pagbajabyn</forename><surname>Nymadawa</surname></persName>
							<affiliation key="aff67">
								<orgName type="institution" key="instit1">National Influenza Center</orgName>
								<orgName type="institution" key="instit2">National Center of Communicable Diseases</orgName>
								<orgName type="institution" key="instit3">Ministry of Health</orgName>
								<address>
									<settlement>Ulaanbaatar</settlement>
									<country key="MN">Mongolia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bulent</forename><surname>Ozbay</surname></persName>
							<affiliation key="aff68">
								<orgName type="department">Department of Pulmonary and Critical Care</orgName>
								<orgName type="institution">Yuzuncu Yil University Medical Faculty</orgName>
								<address>
									<settlement>Van</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mehpare</forename><surname>Ozkan</surname></persName>
							<affiliation key="aff69">
								<orgName type="department">Clinic of Pediatric Neurology</orgName>
								<orgName type="institution">Dr. Sami Ulus Research and Training Hospital of Women&apos;s and Children&apos;s Health and Diseases</orgName>
								<address>
									<settlement>Ankara</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dhruv</forename><surname>Parekh</surname></persName>
							<affiliation key="aff70">
								<orgName type="department">School of Clinical and Experimental Medicine</orgName>
								<orgName type="laboratory">Critical Care and Pain Perioperative, Critical Care and Trauma Trials Group</orgName>
								<orgName type="institution">University of Birmingham</orgName>
								<address>
									<settlement>Birmingham</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mical</forename><surname>Paul</surname></persName>
							<affiliation key="aff71">
								<orgName type="department">Division of Infectious Diseases</orgName>
								<orgName type="institution">Rambam Health Care Campus</orgName>
								<address>
									<settlement>Haifa</settlement>
									<country key="IL">Israel</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wolfgang</forename><surname>Poeppl</surname></persName>
							<affiliation key="aff72">
								<orgName type="institution">Medical University of Vienna</orgName>
								<address>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Fernando</forename><forename type="middle">P</forename><surname>Polack</surname></persName>
							<affiliation key="aff73">
								<orgName type="department">Department of Pediatrics</orgName>
								<orgName type="institution">Vanderbilt University</orgName>
								<address>
									<addrLine>Vanderbilt Vaccine Center</addrLine>
									<settlement>Nashville</settlement>
									<region>TN</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff74">
								<orgName type="department">Fundacion INFANT</orgName>
								<address>
									<settlement>Buenos Aires</settlement>
									<country key="AR">Argentina</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Barbara</forename><forename type="middle">A</forename><surname>Rath</surname></persName>
							<affiliation key="aff75">
								<orgName type="department" key="dep1">Division of Pneumonology-Immunology</orgName>
								<orgName type="department" key="dep2">Department of Pediatrics</orgName>
								<orgName type="institution">Charite ´University Medical Center</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alejandro</forename><forename type="middle">H</forename><surname>Rodr</surname></persName>
							<affiliation key="aff76">
								<orgName type="department">Critical Care Department</orgName>
								<orgName type="institution" key="instit1">Hospital Joan XXIII</orgName>
								<orgName type="institution" key="instit2">IISPV</orgName>
								<orgName type="institution" key="instit3">URV, CIBERES</orgName>
								<address>
									<settlement>Tarragona</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marilda</forename><forename type="middle">M</forename><surname>Siqueira</surname></persName>
							<affiliation key="aff77">
								<orgName type="laboratory">Laboratory of Respiratory Viruses</orgName>
								<orgName type="institution">Oswaldo Cruz Institute/Fiocruz</orgName>
								<address>
									<settlement>Rio de Janeiro</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Joanna</forename><surname>Skre Z T-Magierło</surname></persName>
							<affiliation key="aff78">
								<orgName type="institution">Uniwersytet Rzeszowski</orgName>
								<address>
									<addrLine>Rzeszo ´w</addrLine>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ewa</forename><surname>Talarek</surname></persName>
							<affiliation key="aff79">
								<orgName type="department">Department of Children&apos;s Infectious Diseases</orgName>
								<orgName type="institution">Medical University of Warsaw</orgName>
								<address>
									<settlement>Warsaw</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Julian</forename><forename type="middle">W</forename><surname>Tang</surname></persName>
							<affiliation key="aff80">
								<orgName type="department" key="dep1">Division of Microbiology/Molecular Diagnostic Centre</orgName>
								<orgName type="department" key="dep2">Department of Laboratory Medicine</orgName>
								<orgName type="institution">National University Hospital</orgName>
								<address>
									<settlement>Singapore</settlement>
									<country key="SG">Singapore</country>
								</address>
							</affiliation>
							<affiliation key="aff81">
								<orgName type="department">Alberta Provincial Laboratory for Public Health</orgName>
								<orgName type="institution">University of Alberta Hospital</orgName>
								<address>
									<settlement>Edmonton</settlement>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
							<affiliation key="aff82">
								<orgName type="department">Department of Medical Microbiology and Immunology</orgName>
								<orgName type="institution">University of Alberta</orgName>
								<address>
									<settlement>Edmonton</settlement>
									<region>AB</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Antoni</forename><surname>Torres</surname></persName>
							<affiliation key="aff83">
								<orgName type="institution" key="instit1">Hospital Clinic</orgName>
								<orgName type="institution" key="instit2">University of Barcelona</orgName>
								<orgName type="institution" key="instit3">IDIBAPS</orgName>
								<orgName type="institution" key="instit4">CIBERES</orgName>
								<address>
									<settlement>Barcelona</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Selda</forename><forename type="middle">H</forename><surname>T€ Or€</surname></persName>
							<affiliation key="aff84">
								<orgName type="department" key="dep1">Department of Pediatric Infectious Diseases</orgName>
								<orgName type="department" key="dep2">Istanbul Medical Faculty</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dat</forename><surname>Tran</surname></persName>
							<affiliation key="aff85">
								<orgName type="department" key="dep1">Division of Infectious Diseases</orgName>
								<orgName type="department" key="dep2">Department of Paediatrics</orgName>
								<orgName type="department" key="dep3">The Hospital for Sick Children</orgName>
								<orgName type="institution">University of Toronto</orgName>
								<address>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Timothy</forename><forename type="middle">M</forename><surname>Uyeki</surname></persName>
							<affiliation key="aff86">
								<orgName type="department" key="dep1">Influenza Division</orgName>
								<orgName type="department" key="dep2">National Center for Immunization and Respiratory Diseases</orgName>
								<orgName type="department" key="dep3">Centers for Disease Control and Prevention</orgName>
								<address>
									<settlement>Atlanta</settlement>
									<region>GA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Annelies</forename><surname>Van Zwol</surname></persName>
							<affiliation key="aff87">
								<orgName type="department">Department of Pediatric Intensive Care</orgName>
								<orgName type="institution">VU University Medical Center</orgName>
								<address>
									<settlement>Amsterdam</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wendy</forename><surname>Vaudry</surname></persName>
							<affiliation key="aff88">
								<orgName type="department" key="dep1">Division of Infectious Diseases</orgName>
								<orgName type="department" key="dep2">Department of Pediatrics, Stollery Children&apos;s Hospital</orgName>
								<orgName type="institution">University of Alberta</orgName>
								<address>
									<settlement>Edmonton</settlement>
									<region>AB</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Daiva</forename><surname>Velyvyte</surname></persName>
							<affiliation key="aff89">
								<orgName type="institution">Lithuanian University of Health Sciences</orgName>
								<address>
									<settlement>Kaunas</settlement>
									<country key="LT">Lithuania</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tjasa</forename><surname>Vidmar</surname></persName>
							<affiliation key="aff90">
								<orgName type="institution">General Hospital</orgName>
								<address>
									<settlement>Slovenj Gradec</settlement>
									<country key="SI">Slovenia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Paul</forename><surname>Zarogoulidis</surname></persName>
							<affiliation key="aff91">
								<orgName type="laboratory">Unit of Infectious Diseases</orgName>
								<orgName type="institution" key="instit1">University General Hospital of Alexandroupolis</orgName>
								<orgName type="institution" key="instit2">Democritus University Thrace</orgName>
								<address>
									<settlement>Dragana</settlement>
									<country key="GR">Greece</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pride</forename><surname>Consortium</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jonathan</forename><forename type="middle">S</forename><surname>Nguyen-Van-Tam</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Epidemiology and Public Health</orgName>
								<orgName type="institution">University of Nottingham</orgName>
								<address>
									<settlement>Nottingham</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mohammed</forename><surname>V-Souissi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Morocco</forename><surname>Rabat</surname></persName>
						</author>
						<author>
							<affiliation key="aff26">
								<orgName type="institution">Inserm/University of La Re ´union/URML-OI), CHU Saint Pierre</orgName>
								<address>
									<addrLine>Saint Pierre</addrLine>
									<settlement>La Réunion</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff92">
								<orgName type="department">Clinical Sciences Building</orgName>
								<orgName type="institution" key="instit1">University of Nottingham</orgName>
								<orgName type="institution" key="instit2">City Hospital</orgName>
								<address>
									<addrLine>Room A28b</addrLine>
									<postCode>NG5 1PB</postCode>
									<settlement>Nottingham</settlement>
									<region>DM</region>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Impact of neuraminidase inhibitors on influenza A(H1N1) pdm09-related pneumonia: an individual participant data meta-analysis</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">D327F15B7A18500844E59AA9A0E5F003</idno>
					<idno type="DOI">10.1111/irv.12363</idno>
					<note type="submission">Accepted 9 November 2015.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:15+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Hospitalisation</term>
					<term>individual participant data meta-analyses</term>
					<term>influenza-related pneumonia</term>
					<term>neuraminidase inhibitors</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Please cite this paper as: Muthuri et al. (2016) Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis.</s><s>Influenza and Other Respiratory Viruses 10(3), 192-204.</s></p><p><s>NAIs for influenza-related pneumonia</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background The impact of neuraminidase inhibitors (NAIs) on influenza-related pneumonia (IRP) is not established.</s><s>Our objective was to investigate the association between NAI treatment and IRP incidence and outcomes in patients hospitalised with A(H1N1) pdm09 virus infection.</s></p><p><s>Methods A worldwide meta-analysis of individual participant data from 20 634 hospitalised patients with laboratory-confirmed A (H1N1)pdm09 (n = 20 021) or clinically diagnosed (n = 613) 'pandemic influenza'.</s><s>The primary outcome was radiologically confirmed IRP.</s><s>Odds ratios (OR) were estimated using generalised linear mixed modelling, adjusting for NAI treatment propensity, antibiotics and corticosteroids.</s></p><p><s>Results Of 20 634 included participants, 5978 (29Á0%) had IRP; conversely, 3349 (16Á2%) had confirmed the absence of radiographic pneumonia (the comparator).</s><s>Early NAI treatment (within 2 days of symptom onset) versus no NAI was not significantly associated with IRP [adj.</s><s>OR 0Á83 (95% CI 0Á64-1Á06; P = 0Á136)].</s><s>Among the 5978 patients with IRP, early NAI treatment versus none did not impact on mortality [adj.</s><s>OR = 0Á72 (0Á44-1Á17; P = 0Á180)] or likelihood of requiring ventilatory support [adj.</s><s>OR = 1Á17 (0Á71-1Á92; P = 0Á537)], but early treatment versus later significantly reduced mortality [adj.</s><s>OR = 0Á70 (0Á55-0Á88; P = 0Á003)] and likelihood of requiring ventilatory support [adj.</s><s>OR = 0Á68 (0Á54-0Á85; P = 0Á001)].</s></p><p><s>Conclusions Early NAI treatment of patients hospitalised with A (H1N1)pdm09 virus infection versus no treatment did not reduce the likelihood of IRP.</s><s>However, in patients who developed IRP, early NAI treatment versus later reduced the likelihood of mortality and needing ventilatory support.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>2]<ref type="bibr" target="#b15">[3]</ref><ref type="bibr" target="#b16">[4]</ref><ref type="bibr" target="#b17">[5]</ref> Neuraminidase inhibitors (NAIs), primarily oseltamivir and zanamivir, were widely recommended for patients with suspected or confirmed influenza A(H1N1)pdm09 virus infection. <ref type="bibr" target="#b18">6,</ref><ref type="bibr" target="#b19">7</ref></s><s>]<ref type="bibr" target="#b22">[10]</ref> The findings from meta-analyses have been inconsistent.</s><s>One study based on observational data from 150 660 patients with mainly seasonal influenza suggested no statistically significant reduced likelihood of pneumonia. <ref type="bibr" target="#b21">9</ref></s><s>Another used clinical trials data from 4452 community adult patients with uncomplicated seasonal influenza and concluded that oseltamivir significantly reduced 'self-reported, investigator-mediated, unverified pneumonia' by 45%, compared with placebo, but data on radiologically confirmed pneumonia were not available. <ref type="bibr" target="#b23">11</ref></s><s> recent individual participant data (IPD) analysis of clinical trial data investigating the efficacy of oseltamivir when compared to placebo in patients with seasonal influenza reported a reduction in risk of pneumonia by 60%. <ref type="bibr" target="#b24">12</ref> Individual observational studies during the 2009-2010 pandemic suggest a possible benefit of NAIs in reducing pneumonia incidence, but are limited by small sample sizes.</s><s><ref type="bibr" target="#b25">[13]</ref><ref type="bibr" target="#b26">[14]</ref><ref type="bibr" target="#b27">[15]</ref><ref type="bibr" target="#b28">[16]</ref> A meta-analysis of 2009-2010 pandemic data from patients hospitalised with influenza A(H1N1)pdm09 virus infection reported that early treatment with NAIs reduced the likelihood of IRP compared to late treatment by 65%.</s><s><ref type="bibr" target="#b29">17</ref> But this work encountered high degrees of heterogeneity and inconsistent or incomplete adjustment for potential confounders.</s></p><p><s>We present a global meta-analysis based on IPD, controlling for potential confounders and treatment propensity.</s><s>We investigate the association between NAI treatment and radiologically confirmed IRP in patients hospitalised with A(H1N1)pdm09 virus infection, and outcomes including admission to intensive care units (ICUs), ventilatory support, acute respiratory distress syndrome (ARDS) and mortality in patients with IRP.</s><s>Some of these results have been previously reported in the form of an abstract. <ref type="bibr" target="#b30">18</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methodology</head><p><s>The PRIDE research consortium Details of the Post-pandemic Review of anti-Influenza Drug Effectiveness (PRIDE) study have been published previously. <ref type="bibr" target="#b31">19</ref></s><s>Briefly, participating research centres were identified during the conduct of a systematic review of published studies on the same topic. <ref type="bibr" target="#b29">17</ref></s><s>Additional centres were recruited through this network of global collaborators, publicity at conferences and by word of mouth.</s><s>Centres that fulfilled the minimum data set requirements (Table <ref type="table" target="#tab_5">S2</ref>) were eligible for inclusion in the consortium.</s><s>In total, 79 research groups from 38 countries and six World Health Organization (WHO) regions contributed data on 143 786 patients with laboratory-or clinically diagnosed influenza A(H1N1)pdm09 virus infection (Figure <ref type="figure">1</ref>).</s><s>No data were provided or funded for collection by pharmaceutical companies.</s><s>The protocol was registered with the PROSPERO register of systematic reviews, number CRD42011001273. <ref type="bibr" target="#b32">20</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data standardisation, exposure and outcome variables</head><p><s>Data were standardised using a common data dictionary <ref type="bibr" target="#b31">19</ref> before pooling for analysis.</s><s>For this analysis, the primary outcome was IRP defined as laboratory-confirmed or clinically diagnosed influenza A(H1N1)pdm09 virus infection plus pneumonia confirmed by chest radiography, occurring at any time after the onset of influenza-like illness.</s><s>For radiographic evidence of pneumonia, we accepted: The absence of IRP ('no IRP') was defined as laboratoryconfirmed or clinically diagnosed influenza A(H1N1)pdm09 infection plus a radiographic report that did not identify abnormalities consistent with pneumonia, or which stated that pneumonia was 'not present' (irrespective of any specific features reported).</s></p><p><s>Comparative exposure to NAI treatment was defined as follows: early NAI treatment (≤2 days after symptom onset) versus no NAI treatment; early NAI treatment versus later NAI treatment (treatment commenced &gt;2 days after symptom onset); later NAI treatment versus no NAI treatment; and NAI treatment (irrespective of timing) versus no NAI treatment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Propensity scoring</head><p><s>Propensity scores for the likelihood of NAI treatment were calculated for each patient within individual data sets using multivariable logistic regression for each of the three NAI exposure measures, using covariates as described by Muthuri et al. <ref type="bibr" target="#b31">19</ref> (Table <ref type="table">S3</ref>).</s><s>Subsequently, propensity scores were categorised into quintiles for each individual data set.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>To investigate the association between the use of NAI treatment and IRP, we compared patients with IRP against those with no IRP.</s><s>We used generalised linear mixed modelling to conduct separate analyses for each NAI exposure comparison using the xtmelogit command in STATA (version 13; StataCorp LP, College Station, TX, USA).</s></p><p><s>Individual studies were included in the model as a random intercept in order to account for differences in baseline outcome.</s><s>Adjustment was performed for propensity of NAI treatment, antibiotics administered during hospitalisation and corticosteroids administered during hospitalisation.</s><s>Missing data in the covariates were included as a separate dummy category to allow for comparisons across the crude and adjusted analyses.</s><s>We excluded data sets in which all patients (n = 1352 from 14 data sets) were diagnosed with IRP.</s><s>Stratified analyses were conducted for adults (≥16 years), children (&lt;16 years; including &lt;5and 5-to 15-year subgroups), pregnant women, laboratory-confirmed A(H1N1)pdm09 cases and patients admitted to critical care units.</s><s>We did not include patients with unknown pneumonia status (n = 3615 across 21 data sets) in this analysis.</s><s>In the subgroup of patients with IRP, we further examined the effect of NAI treatment on secondary clinical outcomes: admission to ICUs, ventilatory support, ARDS and mortality.</s><s>At this juncture, we re-included the 14 data sets in which all patients were diagnosed with IRP.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sensitivity analysis</head><p><s>In some clinical settings, chest radiography is not routinely performed for hospitalised patients with influenza unless a pulmonary complication is also suspected; therefore, reliance on radiographic abnormalities is likely to give a conservative estimate of pneumonia incidence.</s><s>Accordingly, we also performed a sensitivity analysis, which considered a diagnosis of 'any pneumonia' by combining IRP with physiciandiagnosed pneumonia (PDP), the latter defined as laboratory-confirmed or clinically diagnosed influenza A(H1N1) pdm09 plus a physician diagnosis of pneumonia, but where no chest radiograph report was available.</s><s>For this analysis, patients categorised as 'no pneumonia' had laboratoryconfirmed or clinically diagnosed influenza A(H1N1)pdm09 with no evidence of IRP on chest radiography; unknown pneumonia status; or, in the absence of a chest radiograph report, no documented clinical record of PDP, recognising that clinicians record positive findings in the case record, but not all negative findings.</s></p><p><s>Results are presented as unadjusted and adjusted odds ratios (OR) with 95% confidence intervals (95% CI), and two-sided P-values &lt; 0Á05 were considered statistically significant.</s><s>Statistical analyses were conducted using STATA (version 13).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>Overall, data were obtained on 35 169 individuals hospitalised with A(H1N1)pdm09 virus infection (Figure <ref type="figure">1</ref>).</s><s>Of these, 29 512 (84%) patients were admitted from January 2009 through March 2011 (Figure <ref type="figure">S1</ref>) with information available on NAI treatment.</s><s>A further eight data sets comprising 8878 hospitalised patients that did not provide data on pneumonia status were excluded from the analysis (Figure <ref type="figure">1</ref>; Table <ref type="table">S4</ref>).</s></p><p><s>Of the 20 634 patients included, 9327 (45%) had a positive or negative diagnosis of IRP confirmed by chest radiography, while 7692 (37%) did not have chest radiography, but had a positive or negative diagnosis of PDP documented.</s><s>The remaining 3615 (18%) hospitalised patients had neither radiological nor clinical documentation of pneumonia status; they were included in the sensitivity analysis (only) as having 'no pneumonia'.</s><s>The characteristics of hospitalised patients with and without pneumonia included in the pooled data set are shown in Table <ref type="table" target="#tab_2">1</ref>.</s><s>Baseline characteristics of each constituent data set included in the analysis are presented in Table <ref type="table">S5</ref>.</s></p><p><s>Overall, patients with IRP were more likely than patients with no IRP to be adult (P &lt; 0Á001), non-pregnant (P &lt; 0Á001), free of underlying medical conditions (P = 0Á038), be from outside the WHO European region (P &lt; 0Á001) and have laboratory-confirmed influenza A (H1N1)pdm09 infection (P &lt; 0Á001).</s><s>They were more likely to receive NAI treatment (P &lt; 0Á001), antibiotics (P &lt; 0Á001) and corticosteroids (P &lt; 0Á001), be admitted to critical care facilities (P &lt; 0Á001) and require ventilatory support (&lt;0Á001) or die (P &lt; 0Á001) (Table <ref type="table" target="#tab_2">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Association between NAI treatment and IRP</head><p><s>Overall, 63 data sets provided data on 9327 hospitalised patients with a positive or negative diagnosis of pneumonia confirmed by chest radiography.</s><s>After the exclusion of 14 data sets in which all patients had IRP (n = 1352, Table <ref type="table">S5</ref>), 7975 patients remained in the analysis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Early NAI (≤2 days) versus no NAI treatment</head><p><s>Early NAI use compared with no NAI use was not significantly associated with IRP in our overall sample [adjusted OR 0Á83 (95% CI 0Á64-1Á06)], nor when we considered laboratory-confirmed cases, adults, pregnant women or children (Table <ref type="table" target="#tab_5">2</ref> and Figure <ref type="figure" target="#fig_0">2</ref>).</s><s>However, point estimates for subgroups tended to suggest an OR below unity, except in ICU patients.</s><s>When considering 'any pneumonia', we found a borderline significant reduced OR associated with early NAI use in all patients [adjusted OR 0Á83 (95% CI 0Á70-0Á98)], with further borderline significant risk reductions also noted among laboratory-confirmed cases; these findings lost a statistical significance when further stratified by patient subgroups but the point estimates remained consistent (Table <ref type="table" target="#tab_5">2</ref>).</s></p><p><s>For this exposure, we also looked at the impact of corticosteroids on the association between NAI treatment and IRP.</s><s>A test for interaction between NAI treatment and corticosteroids did not show any significant interaction (Pvalue: 0Á275).</s><s>Stratified analysis (by corticosteroid use) did not show any significant association between NAI use and IRP (Table <ref type="table">S9</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Early NAI (≤2 days) versus later NAI (&gt;2 days) treatment</head><p><s>Early NAI treatment compared with later was associated with significantly lower odds of IRP [adjusted OR, 0Á43 (95% CI, 0Á37-0Á51)] (Table <ref type="table" target="#tab_5">2</ref> and Figure <ref type="figure" target="#fig_0">2</ref>).</s><s>The odds ratios did not change substantially when only cases of laboratory-confirmed influenza were considered (Table <ref type="table" target="#tab_5">2</ref>).</s><s>Similarly, statistically significant lower odds of IRP were observed in adults aged 16 years or older, children aged 0-15 years, pregnant women and among adult patients admitted to critical care.</s><s>However, there was no statistically significant association with IRP among children admitted to critical care (Table <ref type="table" target="#tab_5">2</ref>).</s><s>The pattern of these findings in terms of direction and significance was similar when considering 'any pneumonia' (Table <ref type="table" target="#tab_5">2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Later NAI (&gt;2 days) versus no NAI treatment</head><p><s>Neuraminidase inhibitor treatment beyond 2 days of symptom onset compared with no NAI was associated with statistically significant higher odds of IRP [adjusted OR, 1Á70 (95% CI, 1Á34-2Á17)].</s><s>Similar statistically significant associations were observed among cases of laboratory-confirmed influenza, adults and critically ill children, but not among all children, pregnant women and critically ill adults.</s><s>Likewise, with 'any pneumonia', the direction and statistical significance of these findings did not change (Table <ref type="table" target="#tab_5">2</ref> and Figure <ref type="figure" target="#fig_0">2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>NAI anytime versus no NAI treatment</head><p><s>After adjustment, the likelihood of IRP in patients treated with NAI (administered at any point after illness onset) was 1Á32 (95% CI 1Á10-1Á59), compared with no NAI treatment (Table <ref type="table" target="#tab_5">2</ref> and Figure <ref type="figure" target="#fig_0">2</ref>).</s><s>This OR did not change substantially when only patients with laboratory-confirmed A(H1N1) pdm09 were included [adjusted OR 1Á29 (95% CI 1Á06-1Á57)].</s><s>Similarly, we observed significantly higher odds of IRP associated with NAI antiviral use in adults and borderline significantly increased odds of IRP in adults admitted to an ICU.</s><s>However, there was no significant association between NAI treatment and IRP in children aged 0-15 years, pregnant women and critically ill children.</s><s>The pattern of these findings was not changed by considering 'any pneumonia', except in children admitted to critical care where we observed statistically significant higher odds of IRP for patients treated with an NAI (at any time).</s></p><p><s>Post hoc analyses on non-ICU patients (all ages) are shown in Table <ref type="table">S6</ref>; children's subgroups aged &lt;5 years and 5-15 are shown in Tables S7 (all severities) and S8 (critically ill).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Impact of NAI treatment on clinical outcomes among patients with pneumonia</head><p><s>We performed a further analysis, restricted to patients with IRP (n = 5978) (Table <ref type="table">3</ref>), and a sensitivity analysis by including 'any pneumonia' patients (n = 7054).</s><s>Data sets in which all patients had IRP (n = 1352 patients, 14 data sets) were re-added at this juncture.</s></p><p><s>In the IRP cohort, we did not observe any statistically significant associations with clinical outcomes when early NAI treatment was compared with no NAI treatment; but for 'any pneumonia', we observed that early NAI treatment versus no NAI was associated with an increased likelihood of admission to an ICU [adjusted OR, 1Á81 (95% CI, 1Á27-2Á58); P = 0Á001], but a reduced likelihood of mortality [adj.</s><s>OR, 0Á62 (95% CI, 0Á40-0Á96); P = 0Á032].</s></p><p><s>In patients with IRP, early NAI treatment compared to later NAI was associated with significantly lower odds of ventilatory support [adjusted OR, 0Á68 (95% CI, 0Á54-0Á85); P = 0Á001] and mortality [adjusted OR, 0Á70 (95% CI, 0Á55-0Á88); P = 0Á003].</s><s>These effects were similar and remained statistically significant for 'any pneumonia'.</s></p><p><s>Later NAI treatment versus no NAI was significantly associated with increased likelihood of ICU admission and ventilatory support.</s><s>The pattern of these findings in terms of direction and significance was unchanged when considering 'any pneumonia'.</s><s>Likewise, patients with IRP who received NAI at any time versus no NAI treatment were more likely to be admitted to an ICU [adj.</s><s>OR, 1Á59 (95% CI, 1Á21-2Á09), P = 0Á001] and receive ventilatory support [adj.</s><s>OR, 1Á67 (95% CI, 1Á22-2Á29), P = 0Á001].</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>The strengths of this study include having data on a large number of patients of all ages hospitalised with influenza A (H1N1)pdm09 virus infection (mainly laboratory confirmed) from different geographical regions worldwide.</s><s>Given the practical and ethical constraints likely to be involved in conducting placebo-controlled trials during pandemic periods, the use of large-scale pooled observational data offers the best chance of producing meaningful results on the effect of NAIs on severe outcomes such as pneumonia.</s><s>Our definition of IRP, which required radiographic evidence of pneumonia, represents a conservative estimate of all cases of pneumonia as radiography was not routinely performed for every patient in all participating centres.</s><s>We therefore also performed separate analyses, which included patients with PDP.</s><s>Some patients with PDP would not have had pneumonia (false positives), and thus, we expect that the true effect estimates of the association of NAI with pneumonia and clinical outcomes probably fall somewhere between the values obtained in the analyses for IRP and 'any pneumonia'.</s></p><p><s>However, there are inevitable limitations, based on the use of retrospective observational data.</s><s>Because we found an increase in IRP in several comparisons where we might have expected NAIs to have a protective effect, this suggests that our propensity scoring was not able to fully adjust for the tendency to use NAIs in more severe disease.</s><s>We were unable to fully adjust for severity of illness within each propensity score because the different severity measures used across individual data sets were disparate.</s><s>Furthermore, we included a broad spectrum of pneumonia severity and the available data did not permit stratification according to pneumonia severity (e.g. using CURB65 or the Pneumonia Severity Index).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>NAI treatment and occurrence of pneumonia</head><p><s>Our findings that early initiation of NAI treatment (≤48 hours after illness onset) compared with later was associated with a significant reduction in IRP and 'any pneumonia' corroborate those previously reported from observational data on hospitalised influenza patients. <ref type="bibr" target="#b21">9,</ref><ref type="bibr" target="#b29">17,</ref><ref type="bibr" target="#b31">19</ref></s><s>hese trends were consistently observed across multiple subgroups: laboratory-confirmed influenza, adults, children, pregnant women and adults requiring critical care (but not children).</s><s>For early treatment versus none, highly consistent, protective point estimates were also generated for most comparisons in adults and children, but failed to reach a statistical significance for IRP [possibly due to type II errors (sample size) although they reached borderline significance for 'any pneumonia' (all cases)].</s><s>As such, the results are somewhat incongruent with our previous work, which showed a 50% reduction in mortality associated with early treatment versus none. <ref type="bibr" target="#b30">18</ref></s><s>It is possibly a combination of residual confounding and misclassification of pneumonia that has led to our current results, and it remains plausible that these weak signals still suggest a reduction in the occurrence of IRP.</s></p><p><s>]<ref type="bibr" target="#b37">[24]</ref><ref type="bibr" target="#b38">[25]</ref><ref type="bibr" target="#b39">[26]</ref><ref type="bibr" target="#b40">[27]</ref><ref type="bibr" target="#b41">[28]</ref> Essentially similar observations were made for 'any pneumonia'.</s></p><p><s>Thus, in terms of the occurrence of pneumonia, our data suggest differential effects depending on the timing and use of NAIs; apparent harm associated with any or later NAI use versus no NAI; but potential benefit from early NAI use versus late NAI use or none.</s><s>Based upon what is known *Any pneumonia includes influenza-related pneumonia (IRP) (n = 5978) and physician-diagnosed pneumonia (PDP) (n = 1076).</s><s>**No pneumonia includes no IRP (n = 3349), no PDP (n = 6616) and unknown pneumonia status (n = 3615).</s><s>***All percentages have been calculated using these denominators unless otherwise specified.</s><s>†Reported as clinically obese or using WHO definition for obesity (BMI ≥30 kg/m 2 in adults aged ≥20 years).</s><s>† †Proportions were calculated as a percentage of pregnant patients among female patients of reproductive age (13-54 years); the broader age range was selected in preference to the WHO definition (15-44 years) after consultation with data contributors to reflect the actual fertility experience of the sample.</s><s>† † †For definition of comorbidity, see Table <ref type="table">S3</ref>.</s><s>‡Denominators for pandemic vaccine based on patients admitted after 1 October 2009 (when vaccine potentially became available).</s><s>‡ ‡Percentages calculated as a proportion of the total patients in that category who received neuraminidase inhibitor (NAI) therapy.</s></p><p><s>NAIs for influenza-related pneumonia about the mechanism of action of NAIs, <ref type="bibr" target="#b42">29,</ref><ref type="bibr" target="#b43">30</ref> it is theoretically possible that treatment might be ineffective [tending to produce an odds ratio (OR) close to 1] but rather implau-sible that it would be genuinely harmful, producing an OR &gt; 1 as we measured.</s><s>Instead, we surmise that NAIs were often prescribed after the development of pneumonia or  clinical deterioration; furthermore, patients with IRP were admitted to hospital a median of 4 days from symptom onset, compared to 2 days for those with no pneumonia.</s><s>A process of reverse causation is more likely to be responsible for the elevated risk of IRP associated with any or late NAI treatment versus none.</s><s>Indeed, from our data set, we were able to record the timing of initiation of NAI treatment in relation to illness onset, but we lacked the ability to record the timing of treatment in relation to the development of pneumonia, which precluded us conducting a survival analysis.</s><s>With regard to the severity of illness at the time of initiating NAI therapy, one functional measure would have been to consider site of NAI treatment initiation (outpatient, emergency department, hospital ward, ICU); unfortunately, we were not able to do this because overall there were too many missing data.</s></p><formula xml:id="formula_0">n 2 = 6710) 0Á97 (0Á77-1Á23) 0Á83 (0Á64-1Á06) 1Á02 (0Á87-1Á19) 0Á83 (0Á70-0Á98)* Laboratory-confirmed cases (all ages) (n 1 = 2462; n 2 = 6541) 0Á97 (0Á76-1Á24) 0Á83 (0Á64-1Á08) 1Á02 (0Á87-1Á19) 0Á84 (0Á70-0Á99)* Adults (≥16 years) (n 1 = 1934; n 2 = 3897) 0Á90 (0Á68-1Á17) 0Á80 (0Á60-1Á06) 1Á00 (0Á82-1Á23) 0Á82 (0Á66-1Á02) Children (&lt;16 years) (n 1 = 670; n 2 = 2765) 1Á04 (0Á61-1Á77) 0Á76 (0Á42-1Á36) 0Á89 (0Á69-1Á14) 0Á78 (0Á59-1Á03) Pregnant (13-54 years) (n 1 = 130; n 2 = 424) 0Á88 (0Á27-2Á93) 0Á96 (0Á29-3Á20) 0Á94 (0Á41-2Á18) 0Á67 (0Á26-1Á76) Intensive care unit (ICU) patients (all ages) Adults (≥16 years) (n 1 = 583; n 2 = 1015) 1Á19 (0Á67-2Á13) 1Á09 (0Á59-2Á02) 1Á13 (0Á76-1Á67) 1Á04 (0Á69-1Á56) Children (&lt;16 years) (n 1 = 197; n 2 = 447) 1Á51 (0Á58-3Á97) 1Á33 (0Á46-3Á78) 1Á75 (0Á99-3Á12) 1Á44<label>(</label></formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>NAI treatment and clinical outcomes in pneumonia</head><p><s>Our other main finding relates to the effect of NAI treatment on clinical outcomes in patients with IRP.</s><s>Our data reveal that patients with IRP, who were treated early with an NAI versus later, experienced a roughly one-third lower likelihood of dying or requiring ventilatory support.</s><s>A mortality reduction of similar magnitude was noted when comparing early NAI versus no NAI, which was statistically significant for the analysis of 'any pneumonia', but not for IRP.</s><s>Although we advise caution in the interpretation of these subgroup analyses, essentially the same finding has been made about ventilatory support in a very large cohort of children hospitalised with seasonal and pandemic influenza. <ref type="bibr" target="#b44">31</ref></s><s>e also found that among patients with 'any pneumonia', those who received NAIs were more likely to be managed in an ICU or require ventilatory support compared to those not treated with NAIs, regardless of the timing of treatment.</s><s>Confounding by indication is an important consideration in relation to these data; that is, patients with severe pneumonia or ARDS who were escalated to ICU-based care would be more likely to be preferentially treated with NAIs compared to those not requiring ICU; indeed, in the PRIDE data set overall (n = 29 259), we noted that 82% of ICU patients received an NAI compared with 61% in non-ICU patients (P &lt; 0Á001).</s><s>The alternative explanation that NAI treatment results in clinical deterioration with resultant increased requirements for ICU admission or ventilatory support, but no increase in mortality is unlikely and our results should not be used to justify the avoidance of early empirical use of NAIs for patients who are severely unwell with suspected influenza.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Technical limitations</head><p><s>Insufficient data on influenza vaccination limited our ability to assess its potential effect on the clinical course of influenza A(H1N1)pdm09 virus infection, albeit that 9890 of 20 634 patients (48Á5%) were admitted prior to November 2009 and could not have benefitted from H1N1pdm09 vaccine as it would not have been available by this point.</s><s>There were wide variations across included study centres in terms of individual study period, healthcare systems, clinical practice, treatment policies and resource availability.</s><s>Although we attempted to control for these study-level biases using generalised linear mixed models, residual confounding is possible.</s><s>Likewise, we cannot completely eliminate misclassification of exposure, covariate or outcome variables.</s><s>Notwithstanding, we attempted to account for misclassification bias by conservatively restricting our main analysis to IRP based on chest radiograph reports.</s><s>But we were unable to discriminate between viral pneumonia, bacterial pneumonia and concurrent viral and bacterial pneumonia, nor differentiate between community-and hospital-acquired pneumonia.</s></p><p><s>Despite requesting a minimum set of data variables (Table <ref type="table" target="#tab_5">S2</ref>), the nature of the surveillance data sets provided, which were set up for monitoring during a public health emergency, meant that there were missing data on some variables of interest (e.g.</s><s>admission diagnosis, comorbidities, interval from the onset of symptoms to NAI treatment, severity of disease at presentation, influenza vaccination, concomitant therapies, complications, information on follow-up).</s></p><p><s>Finally, this study does not reflect the full spectrum of disease caused by influenza A(H1N1)pdm09 virus infection in the community as it only examined hospitalised patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Implications and conclusions</head><p><s>Early NAI treatment probably reduces the likelihood of IRP.</s><s>We observed highly consistent protective point estimates for early initiation of NAI treatment versus late and early treatment versus no NAI, but only the former was statistically significant; therefore, the evidence is strongest for an effect of early versus later NAI treatment.</s><s>Overall, NAI treatment compared with no NAI treatment was associated with an increased likelihood of IRP; we surmise this because NAIs are sometimes started later in response to the development of pneumonia.</s></p><p><s>In patients with IRP, early NAI treatment versus later reduced the need for ventilatory support and subsequent mortality.</s><s>Because randomised controlled trials of NAI treatment versus no NAI or placebo, or early NAI treatment versus late, are unlikely to be ethically or practically feasible, further evidence is needed from well-designed, prospective cohort studies in which disease severity and the dates of symptom onset, hospital admission, NAI treatment initiation and pneumonia onset are all accurately and consistently described.</s></p><p><s>grants from Canadian Institutes of Health Research/SickKids Foundation New Investigator Grant XG08-049R, grants from Canadian Institutes of Health Research Catalyst Grant CAT86860, grants from University of Toronto Dean's Fund Pilot Study Grant, during the conduct of the study.</s><s>Wendy Vaudry reports grants from Canadian Pediatric Society, grants from Public Health Agency of Canada, during the conduct of the study.</s><s>Jonathan S Nguyen-Van-Tam reports that a grant from F. Hoffmann-La Roche funded the current study; grants from GlaxoSmith Kline in the area of influenza and non-financial support from ESWI (European Scientific Working Group on Influenza) to lecture on influenza, outside the submitted work; his brother is a current employee of GlaxoSmithKline.</s><s>All other named authors declare no conflict of interests.</s><s>JSN-V-T is Editor-in-Chief of Influenza and Other Respiratory Viruses; however he played no role whatsoever in the editorial process for this paper, including decisions to send the manuscript for independent peer-review or about final acceptance of a revised version.</s><s>All of the above functions were handled independently by Dr Alan Hampson, Senior Editor (formerly Editor-in-Chief).</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2. Summary of main findings for influenza-related pneumonia (IRP) in laboratory-and clinical diagnosed influenza patients, all ages.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>0Á79-2Á62) Early NAI (≤2 days) versus later NAI (&gt;2 days) Laboratory and clinically confirmed (all ages) (n 1 = 5058; n 2 = 10 925) 0Á34 (0Á30-0Á39)*** 0Á43 (0Á37-0Á51)*** 0Á40 (0Á37-0Á45)*** 0Á51 (0Á46-0Á57)*** Laboratory-confirmed cases (all ages) (n 1 = 4834; n 2 = 10 667)</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Table 3 .n 1 =</head><label>31</label><figDesc><div><p><s>Association between neuraminidase inhibitor (NAI) treatment and clinical outcomes among patients with pneumonia Clinical outcomes/exposures studied Influenza-related pneumonia (IRP) Any pneumonia † Crude OR (95% CI) Adjusted † † OR (95% CI) Crude OR (95% CI) Adjusted † † OR (95% CI) Admission to an intensive care unit Early versus no NAI (n 1 = 1480; n 2 = 1855) 1Á51 (1Á01-2Á25)* 1Á44 (0Á94-2Á18) 2Á02 (1Á44-2Á83)*** 1Á81 (1Á27-2Á58)** Early versus later NAI (n 1 = 3905; n 2 = 4709) 1Á15 (0Á94-1Á39) 0Á89 (0Á71-1Á11) 1Á09 (0Á92-1Á29) 0Á95 (0Á79-1Á14) Later versus no NAI (n 1 = 3255; n 2 = 3864) 2Á59 (1Á85-3Á61)*** 2Á43 (1Á71-3Á45)*** 2Á91 (2Á16-3Á91)*** 2Á66 (1Á95-3Á62)*** NAI versus no NAI (n 1 = 5962; n 2 = 6976) 1Á69 (1Á30-2Á19)*** 1Á59 (1Á21-2Á09)** 1Á96 (1Á55-2Á50)*** 1Á78 (1Á38-2Á28)*** Ventilation support Early versus no NAI (n 1 = 1131; n 2 = 1287) 1Á12 (0Á70-1Á79) 1Á17 (0Á71-1Á92) 1Á24 (0Á82-1Á87) 1Á13 (0Á73-1Á75) Early versus later NAI (n 1 = 3084; n 2 = 3459) 0Á69 (0Á56-0Á86)** 0Á68 (0Á54-0Á85)** 0Á74 (0Á60-0Á90)** 0Á75 (0Á61-0Á93)** Later versus no NAI (n 1 = 2489; n 2 = 2760) 2Á31 (1Á50-3Á55)*** 2Á48 (1Á57-3Á92)*** 2Á18 (1Á48-3Á21)*** 2Á21 (1Á47-3Á32)*** NAI versus no NAI (n 1 = 4739; n 2 = 5182) 1Á70 (1Á25-2Á30)** 1Á67 (1Á22-2Á29)** 1Á69 (1Á27-2Á25)*** 1Á59 (1Á19-2Á13)** Acute respiratory distress syndrome Early versus no NAI (n 1 = 454; n 2 = 546) 1Á14 (0Á32-4Á07) 1Á98 (0Á46-8Á54) 2Á26 (0Á76-6Á67) 2Á98 (0Á77-11Á60) Early versus later NAI (n 1 = 1234; n 2 = 1434) 0Á54 (0Á33-0Á90)* 0Á65 (0Á38-1Á11) 0Á55 (0Á37-0Á83)** 0Á61 (0Á40-0Á94)* Later versus no NAI (n 1 = 1032; n 2 = 1178) 2Á34 (0Á98-5Á55) 2Á23 (0Á90-5Á54) 3Á42 (1Á50-7Á82)** 3Á21 (1Á36-7Á58)** NAI versus no NAI (n 1 = 1549; n 2 = 1836) 1Á99 (0Á84-4Á70) 2Á13 (0Á87-5Á21) 3Á06 (1Á35-6Á94)** 3Á14 (1Á37-7Á29)** Mortality Early versus no NAI (n 1 = 1490; n 2 = 1866) 0Á61 (0Á38-0Á96)* 0Á72 (0Á44-1Á17) 0Á59 (0Á39-0Á89)* 0Á62 (0Á40-0Á96)* Early versus later NAI (n 1 = 3906; n 2 = 4711) 0Á84 (0Á67-1Á04) 0Á70 (0Á55-0Á88)** 0Á77 (0Á63-0Á95)* 0Á69 (0Á56-0Á86)** Later versus no NAI (n 1 = 3266; n 2 = 3875) 1Á05 (0Á73-1Á52) 1Á18 (0Á81-1Á74) 1Á06 (0Á76-1Á49) 1Á13 (0Á80-1Á61) NAI versus no NAI (n 1 = 5974; n 2 = 7050) total number of patients included in IRP analysis; n 2 = total number of patients included in any pneumonia analysis.</s><s>*P &lt; 0Á05, **P &lt; 0Á01, ***P &lt; 0Á001.</s><s>†Influenza-related pneumonia and physician-diagnosed pneumonia.</s><s>† †Adjusted for treatment propensity quintiles, corticosteroid use and antibiotic use.</s><s>NAIs for influenza-related pneumonia ª 2015 The Authors.</s><s>Influenza and Other Respiratory Viruses Published by John Wiley &amp; Sons Ltd.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Characteristics of pooled data set of 20 634 patients admitted to hospital with influenza A(H1N1)pdm09 virus infection with and without pneumonia</s></p></div></figDesc><table><row><cell></cell><cell cols="2">Radiologically diagnosed pneumonia</cell><cell></cell><cell></cell></row><row><cell></cell><cell>status</cell><cell></cell><cell cols="2">Radiologically or PDP status</cell></row><row><cell>Characteristics</cell><cell>IRP</cell><cell>No IRP</cell><cell>Any pneumonia*</cell><cell>No pneumonia**</cell></row><row><cell>Number of patients***</cell><cell>5978 (100Á0)</cell><cell>3349 (100Á0)</cell><cell>7054 (100Á0)</cell><cell>13 580 (100Á0)</cell></row><row><cell>Number of male cases</cell><cell>3266 (54Á6)</cell><cell>1879 (56Á0)</cell><cell>3811 (54Á0)</cell><cell>6645 (48Á9)</cell></row><row><cell>Age: median (IQR) in years</cell><cell>36 (17-52)</cell><cell>26 (14-46)</cell><cell>35 (14-51)</cell><cell>22 (8-38)</cell></row><row><cell>Adults (≥16 years)</cell><cell>4560 (76Á3)</cell><cell>2436 (72Á7)</cell><cell>5208 (73Á8)</cell><cell>8482 (62Á5)</cell></row><row><cell>Children (&lt;16 years)</cell><cell>1411 (23Á6)</cell><cell>912 (27Á2)</cell><cell>1821 (25Á8)</cell><cell>4966 (36Á6)</cell></row><row><cell>Obese  †</cell><cell>952 (15Á9)</cell><cell>229 (6Á8)</cell><cell>1072 (15Á2)</cell><cell>744 (5Á5)</cell></row><row><cell>Smoking</cell><cell>914 (15Á3)</cell><cell>481 (14Á4)</cell><cell>958 (13Á6)</cell><cell>867 (6Á4)</cell></row><row><cell>Pregnant women  † †</cell><cell>219 (13Á1)</cell><cell>150 (16Á0)</cell><cell>279/1967 (14Á2)</cell><cell>1153/4397 (26Á2)</cell></row><row><cell>WHO regions</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>African region</cell><cell>28 (0Á5)</cell><cell>1 (0Á03)</cell><cell>31 (0Á4)</cell><cell>10 (0Á1)</cell></row><row><cell>Region of the Americas</cell><cell>2314 (38Á7)</cell><cell>550 (16Á4)</cell><cell>2703 (38Á3)</cell><cell>4948 (36Á4)</cell></row><row><cell>Eastern Mediterranean region</cell><cell>178 (3Á0)</cell><cell>206 (6Á2)</cell><cell>549 (7Á8)</cell><cell>3086 (22Á7)</cell></row><row><cell>European region</cell><cell>2635 (44Á1)</cell><cell>2032 (60Á7)</cell><cell>2932 (41Á6)</cell><cell>4080 (30Á0)</cell></row><row><cell>South-East Asia region</cell><cell>45 (0Á8)</cell><cell>86 (2Á6)</cell><cell>45 (0Á6)</cell><cell>157 (1Á2)</cell></row><row><cell>Western Pacific region</cell><cell>778 (13Á0)</cell><cell>474 (14Á2)</cell><cell>794 (11Á3)</cell><cell>1299 (9Á6)</cell></row><row><cell>A(H1N1)pdm09 diagnosis</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Laboratory confirmed</cell><cell>5755 (96Á3)</cell><cell>3146 (93Á9)</cell><cell>6827 (96Á8)</cell><cell>13 194 (97Á2)</cell></row><row><cell>Clinically diagnosed</cell><cell>223 (3Á7)</cell><cell>203 (6Á1)</cell><cell>227 (3Á2)</cell><cell>386 (2Á8)</cell></row><row><cell>Comorbidities  † † †</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Any comorbidity</cell><cell>3021 (50Á5)</cell><cell>1795 (53Á6)</cell><cell>3531 (50Á1)</cell><cell>5449 (40Á1)</cell></row><row><cell>Asthma</cell><cell>856 (14Á3)</cell><cell>777 (22Á7)</cell><cell>968 (13Á7)</cell><cell>1430 (10Á5)</cell></row><row><cell>COPD</cell><cell>432 (7Á2)</cell><cell>249 (7Á4)</cell><cell>454 (6Á4)</cell><cell>345 (2Á5)</cell></row><row><cell>Other chronic lung disease</cell><cell>492 (8Á2)</cell><cell>525 (15Á7)</cell><cell>648 (9Á2)</cell><cell>1668 (12Á3)</cell></row><row><cell>Heart disease</cell><cell>650 (10Á9)</cell><cell>341 (10Á2)</cell><cell>713 (10Á1)</cell><cell>786 (5Á8)</cell></row><row><cell>Renal disease</cell><cell>278 (4Á7)</cell><cell>113 (3Á4)</cell><cell>328 (4Á7)</cell><cell>349 (2Á6)</cell></row><row><cell>Liver disease</cell><cell>122 (2Á0)</cell><cell>73 (2Á2)</cell><cell>127 (1Á8)</cell><cell>121 (0Á9)</cell></row><row><cell>Cerebrovascular disease</cell><cell>121 (2Á0)</cell><cell>122 (3Á6)</cell><cell>133 (1Á9)</cell><cell>170 (1Á3)</cell></row><row><cell>Neurological disease</cell><cell>436 (7Á3)</cell><cell>237 (7Á1)</cell><cell>492 (7Á0)</cell><cell>508 (3Á7)</cell></row><row><cell>Diabetes</cell><cell>634 (10Á6)</cell><cell>280 (8Á4)</cell><cell>725 (10Á3)</cell><cell>690 (5Á1)</cell></row><row><cell>Immunosuppression</cell><cell>525 (8Á8)</cell><cell>242 (7Á2)</cell><cell>610 (8Á7)</cell><cell>852 (6Á3)</cell></row><row><cell>H1N1pdm09 vaccination  ‡</cell><cell>121/2917 (4Á2)</cell><cell>48/1701 (2Á8)</cell><cell>163/3738 (4Á4)</cell><cell>176/6237 (2Á8)</cell></row><row><cell>Time from symptom onset to</cell><cell>4 (2-6)</cell><cell>2 (1-4)</cell><cell>3 (2-6)</cell><cell>2 (1-4)</cell></row><row><cell>hospital admission, days, median (IQR)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Time from symptom onset to</cell><cell>4 (2-7)</cell><cell>2 (1-4)</cell><cell>4 (2-7)</cell><cell>2 (1-4)</cell></row><row><cell>antiviral treatment, days, median (IQR)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Antiviral agents used</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>No NAI treatment</cell><cell>582 (9Á7)</cell><cell>540 (16Á1)</cell><cell>724 (10Á3)</cell><cell>4336 (31Á9)</cell></row><row><cell>Any NAI</cell><cell>5396 (90Á3)</cell><cell>2809 (83Á9)</cell><cell>6330 (89Á7)</cell><cell>9244 (68Á1)</cell></row><row><cell>Oral oseltamivir  ‡ ‡</cell><cell>5356 (99Á3)</cell><cell>2782 (99Á0)</cell><cell>6263 (98Á9)</cell><cell>9068 (98Á1)</cell></row><row><cell>Intravenous/inhaled zanamivir  ‡ ‡</cell><cell>134 (2Á5)</cell><cell>40 (1Á4)</cell><cell>155 (2Á5)</cell><cell>158 (1Á7)</cell></row><row><cell>Intravenous peramivir  ‡ ‡</cell><cell>42 (0Á8)</cell><cell>5 (0Á2)</cell><cell>42 (0Á7)</cell><cell>7 (0Á1)</cell></row><row><cell>NAI (regimen unknown)  ‡ ‡</cell><cell>1 (0Á02)</cell><cell>5 (0Á2)</cell><cell>17 (0Á3)</cell><cell>82 (0Á9)</cell></row><row><cell>NAI and non-NAI  ‡ ‡</cell><cell>75 (1Á4)</cell><cell>15 (0Á5)</cell><cell>76 (1Á2)</cell><cell>18 (0Á2)</cell></row><row><cell>NAI combination therapy  ‡ ‡</cell><cell>134 (2Á5)</cell><cell>23 (0Á8)</cell><cell>144 (2Á3)</cell><cell>71 (0Á8)</cell></row><row><cell>Early NAI (≤2 days of symptom onset)  ‡ ‡</cell><cell>1067 (19Á8)</cell><cell>1057 (37Á6)</cell><cell>1353 (21Á4)</cell><cell>3459 (37Á4)</cell></row><row><cell>Later NAI (&gt;2 days after symptom onset)  ‡ ‡</cell><cell>2843 (52Á7)</cell><cell>998 (35Á5)</cell><cell>3362 (53Á1)</cell><cell>3221 (34Á8)</cell></row><row><cell>Other in-hospital treatment</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Antibiotics</cell><cell>3604 (60Á3)</cell><cell>1731 (51Á7)</cell><cell>4265 (60Á5)</cell><cell>5521 (40Á7)</cell></row><row><cell>Corticosteroids</cell><cell>1658 (27Á7)</cell><cell>626 (18Á7)</cell><cell>1709 (24Á2)</cell><cell>1024 (7Á5)</cell></row><row><cell>Hospital length of stay, days, median (IQR)</cell><cell>9 (5-17)</cell><cell>5 (3-7)</cell><cell>8 (4-17)</cell><cell>4 (2-7)</cell></row><row><cell>Other patient outcomes</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Acute respiratory distress syndrome</cell><cell>265 (4Á4)</cell><cell>10 (0Á3)</cell><cell>341 (4Á8)</cell><cell>43 (0Á3)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>(Continued)</s></p></div></figDesc><table><row><cell></cell><cell cols="2">Radiologically diagnosed pneumonia</cell><cell></cell><cell></cell></row><row><cell></cell><cell>status</cell><cell></cell><cell cols="2">Radiologically or PDP status</cell></row><row><cell>Characteristics</cell><cell>IRP</cell><cell>No IRP</cell><cell>Any pneumonia*</cell><cell>No pneumonia**</cell></row><row><cell>Ventilation support</cell><cell>2372 (39Á7)</cell><cell>450 (13Á4)</cell><cell>2619 (37Á1)</cell><cell>1059 (7Á8)</cell></row><row><cell>Admission to critical care</cell><cell>3335 (55Á8)</cell><cell>764 (22Á8)</cell><cell>3859 (54Á7)</cell><cell>1989 (14Á7)</cell></row><row><cell>Mortality</cell><cell>903 (15Á1)</cell><cell>90 (2Á7)</cell><cell>1014 (14Á4)</cell><cell>496 (3Á7)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Association between NAI treatment and pneumonia</s></p></div></figDesc><table><row><cell></cell><cell cols="2">Influenza-related pneumonia (IRP)</cell><cell>Any pneumonia  †</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Adjusted  † † OR</cell><cell>Crude OR</cell><cell></cell></row><row><cell>Subgroups</cell><cell>Crude OR (95% CI)</cell><cell>(95% CI)</cell><cell>(95% CI)</cell><cell>Adjusted  † † OR (95% CI)</cell></row><row><cell>Early NAI (≤2 days) versus no NAI treatment</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Laboratory and clinically confirmed</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>(all ages) (n 1 = 2605;</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">ª 2015 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley &amp; Sons Ltd.</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">NAIs for influenza-related pneumonia ª 2015 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley &amp; Sons Ltd.</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>We thank the many medical personnel and other individuals who helped in collating and maintaining the clinical data used in our analyses.</s><s>We thank all participating hospitals, institutions and research networks (listed in</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Funding</head><p><s>The PRIDE study is funded via an unrestricted educational grant from F. Hoffmann-La Roche, Switzerland [the manufacturers of Oseltamivir (Tamiflu â )].</s><s>The funder has had no role in protocol design, no opportunity to comment on it and no opportunity to see it other than via the PROSPERO website; no access to any data (and no rights to future access); no role in analysis or interpretation; no opportunity to preview results/findings before entry into the public domain; no opportunity to contribute to, preview or comment on manuscripts and presentations arising from this work.</s><s>The research contract between the University of Nottingham and the funder is freely available for inspection (commercial details redacted) at: http://www.nottingham.ac.uk/research/groups/healthprotection/projects/pride.aspx.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of interest</head><p><s>Puja R Myles and Jo Leonardi-Bee are recipients of grants from F. Hoffmann-La Roche, during the conduct of the study.</s><s>Wei Shen Lim reports unrestricted investigator-</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Author contributions</head><p><s>JSN-V-T, PRM, WSL, JL-B, SGM and SV conceived and designed the study.</s><s>All authors, apart from SGM, SV, JL-B and WSL, contributed to the acquisition and local preparation of constituent data sets.</s><s>SGM, SV, PRM and JL-B contributed to data set amalgamation and standardisation, design of statistical analyses and data analysis.</s><s>JSN-V-T, PRM, JL-B, WSL, SGM and SV interpreted the data and wrote the paper.</s><s>All authors contributed to critical examination of the paper for important intellectual content and approval of the final report.</s><s>Each author acts as the guarantor of data from their individual study centre; JSN-V-T and PRM act as overall guarantors for the pooled analysis and the report.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Appendix 1: PRIDE Consortium Investigators</head><p><s>Maria de Lourdes Aguiar-Oliveira, Tarig SA Al Khuwaitir, Malakita Al Masri, Robed Amin, Elena Ballester-Orcal, Jing</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supporting Information</head><p><s>Additional Supporting Information may be found in the online version of this article:</s></p><p><s>Figure <ref type="figure">S1</ref>.</s><s>Date of admission of 29 512 patients hospitalized with A(H1N1)pdm09 infection (by month).</s></p><p><s>Table <ref type="table">S1</ref>.</s><s>PRIDE study Investigators.</s><s>Table <ref type="table">S2</ref>.</s><s>Minimum dataset requirement.</s><s>Table <ref type="table">S3</ref>.</s><s>Standardised datasetdata dictionary with definitions used in this analysis.</s></p><p><s>Table <ref type="table">S4</ref>.</s><s>Comparison of hospitalised patients included in analysis compared with excluded patients.</s></p><p><s>Table <ref type="table">S5</ref>.</s><s>Characteristics of individual studies contributing to the current analysis.</s></p><p><s>Table <ref type="table">S6</ref>.</s><s>Sensitivity analysis excluding all ICU patients.</s><s>Table <ref type="table">S7</ref>.</s><s>Association between NAI treatment and pneumonia (all children).</s></p><p><s>Table <ref type="table">S8</ref>.</s><s>Association between NAI treatment and pneumonia (critically ill children).</s></p><p><s>Table <ref type="table">S9</ref>.</s><s>Stratified analysis based on steroid use.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title level="m">0Á34 (0Á29-0Á39)*** 0Á43 (0Á36-0Á51)*** 0Á41 (0Á36-0Á46)*** 0Á51 (0Á45-0Á58)***</title>
				<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<idno>0Á26 (0Á13-0Á53)*** 0Á32 (0Á13-0Á75)** 0Á27</idno>
		<title level="m">0Á17-0Á44)*** 0Á34 (0Á20-0Á58)*** ICU patients (all ages) Adults (≥16 years) (n 1 = 1846; n 2 = 2850) 0Á38 (0Á29-0Á51)*** 0Á47 (0Á34-0Á63)*** 0Á55 (0Á45-0Á68)*** 0Á62 (0Á50-0Á77)***</title>
				<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title level="m">2Á53 (2Á02-3Á16)*** 1Á70 (1Á34-2Á17)*** 2Á41 (2Á09-2Á79)*** 1Á57 (1Á34-1Á84)***</title>
				<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<title level="m">2Á51 (1Á98-3Á16)*** 1Á68 (1Á30-2Á16)*** 2Á38 (2Á06-2Á76)*** 1Á55 (1Á32-1Á82)***</title>
				<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<title level="m">2Á29 (1Á78-2Á95)*** 1Á64 (1Á25-2Á16)*** 2Á30 (1Á91-2Á77)*** 1Á58 (1Á29-1Á92)*** Children (&lt;16 years</title>
				<imprint/>
	</monogr>
	<note>n 1 = 724; n 2 = 2598) 2Á26 (1Á28-3Á99)** 1Á68 (0Á89-3Á16</note>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title level="m">1Á99 (1Á55-2Á57)*** 1Á42 (1Á08-1Á87)**</title>
				<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title level="m">5Á84 (1Á50-22Á75)* 4Á25 (1Á07-16Á88)* 3Á50 (1Á90-6Á46)*** 2Á63 (1Á39-4Á96)**</title>
				<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<monogr>
		<title level="m">1Á57 (1Á32-1Á86)*** 1Á32 (1Á10-1Á59)** 1Á62 (1Á45-1Á81)*** 1Á22 (1Á08-1Á38)**</title>
				<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<title level="m">1Á55 (1Á29-1Á86)*** 1Á29 (1Á06-1Á57)* 1Á58 (1Á41-1Á78)*** 1Á19 (1Á05-1Á35)**</title>
				<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title level="m">1Á53 (1Á24-1Á91)*** 1Á30 (1Á03-1Á63)* 1Á63 (1Á40-1Á89)*** 1Á24 (1Á06-1Á46)** Children (&lt;16 years) (n 1 = 2005; n 2 = 6760) 1Á38 (1Á00-1Á90)* 1Á30</title>
				<imprint>
			<biblScope unit="page" from="0" to="92" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<title level="m">1Á41 (1Á18-1Á69)*** 1Á18 (0Á97-1Á43)</title>
				<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<monogr>
		<title level="m">1Á76 (1Á22-2Á53)** 1Á59 (1Á10-2Á30)*</title>
				<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<monogr>
		<title level="m" type="main">†Influenza-related pneumonia and physician-diagnosed pneumonia. † †Adjusted for treatment propensity quintiles, corticosteroid use and antibiotic use</title>
		<author>
			<persName><forename type="first">*p &lt; 0á05</forename></persName>
		</author>
		<author>
			<persName><forename type="first">**p &lt; 0á01</forename></persName>
		</author>
		<author>
			<persName><forename type="first">***p &lt;</forename><surname>0á001</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Complications and outcomes of pandemic 2009 influenza a (H1N1) virus infection in hospitalized adults: how do they differ from those in seasonal influenza?</title>
		<author>
			<persName><forename type="first">N</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Pks</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gcy</forename><surname>Lui</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">203</biblScope>
			<biblScope unit="page" from="1739" to="1747" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Influenza IWGo. Pneumonia and respiratory failure from swineorigin influenza a (H1N1) in Mexico</title>
		<author>
			<persName><forename type="first">R</forename><surname>Perez-Padilla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>De La Rosa-Zamboni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ponce</forename><surname>De Leon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">361</biblScope>
			<biblScope unit="page" from="680" to="689" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Risk factors of a/H1N1 etiology in pneumonia and its impact on mortality</title>
		<author>
			<persName><forename type="first">S</forename><surname>Reyes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Montull</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Martinez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Respir Med</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="page" from="1404" to="1411" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">California Pandemic Working G. Factors associated with death or hospitalization due to pandemic 2009 influenza a(H1N1) infection in California</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Louie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Acosta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Winter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">302</biblScope>
			<biblScope unit="page" from="1896" to="1902" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Influenza Clinical Information N. Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Nguyen-Van-Tam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Pjm</forename><surname>Openshaw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hashim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Thorax</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="645" to="651" />
			<date type="published" when="2009-09">May-September 2009. 2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Influenza antiviral medications: summary for clinicians</title>
		<ptr target="http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm#summary" />
	</analytic>
	<monogr>
		<title level="j">Centers for Disease Control and Prevention</title>
		<imprint>
			<date type="published" when="2014-03-14">Accessed 14 March 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<monogr>
		<title level="m" type="main">Clinical management of human infection with pandemic (H1N1) 2009: Revised guidance</title>
		<ptr target="http://www.who.int/csr/resources/publications/swine-flu/clinical_management_h1n1.pdf.(cited2014" />
		<imprint>
			<date type="published" when="2009-11">2009. November 2009</date>
		</imprint>
	</monogr>
	<note>World Health Organization (WHO)</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations</title>
		<author>
			<persName><forename type="first">L</forename><surname>Kaiser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mills</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mahoney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Hayden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">163</biblScope>
			<biblScope unit="page" from="1667" to="1672" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies</title>
		<author>
			<persName><forename type="first">J</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Santesso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mustafa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">156</biblScope>
			<biblScope unit="page" from="512" to="524" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children</title>
		<author>
			<persName><forename type="first">T</forename><surname>Jefferson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Doshi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page">D008965</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children</title>
		<author>
			<persName><forename type="first">T</forename><surname>Jefferson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Doshi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">D008965</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials</title>
		<author>
			<persName><forename type="first">J</forename><surname>Dobson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Whitley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pocock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Monto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">385</biblScope>
			<biblScope unit="page" from="1729" to="1737" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza a (H1N1): retrospective cohort study</title>
		<author>
			<persName><forename type="first">V</forename><surname>Hiba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chowers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Levi-Vinograd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Rubinovitch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Leibovici</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Paul</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="1150" to="1155" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Characteristics of pregnant Japanese women who required hospitalization for treatment of NAIs for influenza-related pneumonia ª 2015 The Authors. Influenza and Other Respiratory Viruses Published by</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nakai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Minakami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Unno</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Infect</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="232" to="233" />
			<date type="published" when="2011">2011</date>
			<publisher>John Wiley &amp; Sons Ltd</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Pneumonia complicating pandemic (H1N1) 2009: risk factors, clinical features, and outcomes</title>
		<author>
			<persName><forename type="first">D</forename><surname>Viasus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Pano-Pardo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pachon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Medicine</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="328" to="336" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Reducing occurrence and severity of pneumonia due to pandemic H1N1 2009 by early oseltamivir administration: a retrospective study in Mexico</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Higuera Iglesias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kudo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Manabe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">e21838</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Muthuri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Myles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Venkatesan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Leonardi-Bee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Nguyen-Van-Tam</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">207</biblScope>
			<biblScope unit="page" from="553" to="563" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Post-Pandemic Review of Anti-Influenza Drug Effectiveness (Pride Study): An Investigation of the Impact of Neuraminidase Inhibitor Antiviral Use on Pneumonia and Length of Hospital Stay in Hospitalized Influenza A (H1N1)pdm09 Patients</title>
		<author>
			<persName><forename type="first">S</forename><surname>Muthuri</surname></persName>
			<affiliation>
				<orgName type="collaboration">Research Collaboration</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Myles</surname></persName>
			<affiliation>
				<orgName type="collaboration">Research Collaboration</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Leonardi-Bee</surname></persName>
			<affiliation>
				<orgName type="collaboration">Research Collaboration</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Venkatesan</surname></persName>
			<affiliation>
				<orgName type="collaboration">Research Collaboration</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Nguyen-Van-Tam</surname></persName>
			<affiliation>
				<orgName type="collaboration">Research Collaboration</orgName>
			</affiliation>
		</author>
	</analytic>
	<monogr>
		<title level="m">Riga: The European Scientific Workshop on Influenza (ESWI)</title>
				<imprint>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>Abstract</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza a H1N1pdm09 virus infection: a meta-analysis of individual participant data</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Muthuri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Venkatesan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Myles</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Respir Med</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="395" to="404" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<monogr>
		<title level="m" type="main">A systematic review of the impact of neuraminidase inhibitor antiviral use on outcomes of public health importance during the 2009/10 (swine) influenza A/H1N1V pandemic</title>
		<author>
			<persName><forename type="first">P</forename><surname>Myles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Leonardi-Bee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Van-Tam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Muthuri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Venkatesan</surname></persName>
		</author>
		<ptr target="http://www.crd.york.ac.uk/IHR_PROSPERO/display_record.asp?ID=CRD42011001" />
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">#</forename><surname>Uvdwqffnkw8</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2014-02">February 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Imaging of pneumonia: trends and algorithms</title>
		<author>
			<persName><forename type="first">T</forename><surname>Franquet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Respir J</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="196" to="208" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Influenza Clinical Information N. Clinical and laboratory features distinguishing pandemic H1N1 influenza-related pneumonia from interpandemic communityacquired pneumonia in adults</title>
		<author>
			<persName><forename type="first">T</forename><surname>Bewick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Myles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Greenwood</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Thorax</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="247" to="252" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Outcomes of adults hospitalised with severe influenza</title>
		<author>
			<persName><forename type="first">N</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Pks</forename><surname>Chan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Thorax</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="510" to="515" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Treatment with neuraminidase inhibitors for critically ill patients with influenza a (H1N1)pdm09</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Louie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Acosta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="1198" to="1204" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Toronto Invasive Bacterial Diseases N. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario</title>
		<author>
			<persName><forename type="first">A</forename><surname>Mcgeer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Plevneshi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Canada. Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="1568" to="1575" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a global patient registry</title>
		<author>
			<persName><forename type="first">W</forename><surname>Adisasmito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Pks</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">202</biblScope>
			<biblScope unit="page" from="1154" to="1160" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Antiviral treatment for patients hospitalized with severe influenza infection may affect clinical outcomes</title>
		<author>
			<persName><forename type="first">N</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Cockram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Pks</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dsc</forename><surname>Hui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jjy</forename><surname>Sung</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="1323" to="1324" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Viral loads and duration of viral shedding in adult patients hospitalized with influenza</title>
		<author>
			<persName><forename type="first">N</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Pks</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dsc</forename><surname>Hui</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">200</biblScope>
			<biblScope unit="page" from="492" to="500" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">U</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Lew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Williams</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Chem Soc</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="681" to="690" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-nacetylneuraminic acid</title>
		<author>
			<persName><forename type="first">P</forename><surname>Meindl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bodo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Palese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schulman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tuppy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Virology</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="457" to="463" />
			<date type="published" when="1974">1974</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Risk factors for mechanical ventilation in U.S. children hospitalized with seasonal influenza and 2009 pandemic influenza a*</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">O</forename><surname>Eriksson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Graham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Uyeki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Randolph</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatr Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="625" to="631" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
